AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34383006 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated IGRT
Number of subjects: 96
Study 34383006 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionated radiotherapy (CFRT)
Number of subjects: 96
Study 32863352 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency CIA isolates (n = 19)
Number of subjects: 117
Study 32863352 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency CIA isolates (n = 24)
Number of subjects: 117
Study 32863352 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level HA isolates (n = 24)
Number of subjects: 117
Study 32863352 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level HA isolates (n = 19)
Number of subjects: 117
Study 32863352 — intervention group
Group type: EXPERIMENTAL
Intervention: SCM group I
Number of subjects: 117
Study 32863352 — intervention group
Group type: EXPERIMENTAL
Intervention: SCM group II
Number of subjects: 117
Study 32863352 — intervention group
Group type: EXPERIMENTAL
Intervention: SCM allele type 10/type 11
Number of subjects: 117
Study 32863352 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of AMR phenotype/genotype
Number of subjects: 117
Study 32863352 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of AMR phenotype/genotype
Number of subjects: 117
Study 34464438 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM group with multistranded stainless steel wires
Number of subjects: 46
Study 34464438 — intervention group
Group type: COMPARATOR
Intervention: Lab group with multistranded stainless steel wires
Number of subjects: 46
Study 34464438 — intervention group
Group type: COMPARATOR
Intervention: Traditional group with stainless steel Ortho‐FlexTech wires
Number of subjects: 46
Study 34511596 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast wean arm (abrupt discontinuation of NCPAP from 6 cmH2O)
Number of subjects: 66
Study 34511596 — intervention group
Group type: COMPARATOR
Intervention: Slow wean arm (gradual wean of NCPAP at 4 cmH2O, weaning by 1 cmH2O per day)
Number of subjects: 66
Study 35726837 — intervention group
Group type: EXPERIMENTAL
Intervention: HADS six weeks postpartum
Number of subjects: 215
Study 35726837 — intervention group
Group type: EXPERIMENTAL
Intervention: HADS during follow-up
Number of subjects: 215
Study 35726837 — intervention group
Group type: EXPERIMENTAL
Intervention: PCL-5 during follow-up
Number of subjects: 215
Study 35726837 — intervention group
Group type: EXPERIMENTAL
Intervention: PUQE-24 severity measure
Number of subjects: 215
Study 33763527 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based blended-learning tool (intervention group)
Number of subjects: 26
Study 33763527 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching strategy (control group)
Number of subjects: 26
Study 34962159 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) experience, 5-minute video using a head-mounted display
Number of subjects: 40
Study 34962159 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) experience
Number of subjects: 40
Study 34750707 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-display system
Number of subjects: 128
Study 34750707 — intervention group
Group type: COMPARATOR
Intervention: 4K-display system
Number of subjects: 128
Study 33023898 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin adherence (≥80%)
Number of subjects: 868
Study 33023898 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin adherence
Number of subjects: 868
Study 33023898 — intervention group
Group type: EXPERIMENTAL
Intervention: Early adherence to metformin
Number of subjects: 868
Study 33023898 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned strategies to promote adherence
Number of subjects: 868
Study 36134465 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated green coffee extract (DGCE) supplementation, 400 mg capsules, two capsules daily for 12 weeks
Number of subjects: 44
Study 36134465 — intervention group
Group type: COMPARATOR
Intervention: Placebo, two identical capsules daily for 12 weeks
Number of subjects: 44
Study 616774622 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 140
Study 616774622 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 140
Study 35537641 — intervention group
Group type: EXPERIMENTAL
Intervention: Transaxillary thoracic outlet decompression (TA‐TOD)
Number of subjects: 50
Study 35537641 — intervention group
Group type: COMPARATOR
Intervention: Continued conservative treatment
Number of subjects: 50
Study 35537641 — intervention group
Group type: EXPERIMENTAL
Intervention: Transaxillary thoracic outlet decompression (TA‐TOD) after conservative treatment
Number of subjects: 50
Study 33675475 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD) patients
Number of subjects: 80
Study 33675475 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-dialysis CKD G3–5 patients
Number of subjects: 80
Study 33675475 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 80
Study 33675475 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with NAFLD
Number of subjects: 80
Study 33675475 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CKD
Number of subjects: 80
Study 32043533 — intervention group
Group type: EXPERIMENTAL
Intervention: modified constraint‐induced movement therapy (mCIMT)
Number of subjects: 30
Study 32043533 — intervention group
Group type: COMPARATOR
Intervention: conventional therapy
Number of subjects: 30
Study 34693613 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 1020
Study 34693613 — intervention group
Group type: COMPARATOR
Intervention: No dapagliflozin
Number of subjects: 1020
Study 33153937 — intervention group
Group type: EXPERIMENTAL
Intervention: PantoDict digital e‐learning program (Group A)
Number of subjects: 36
Study 33153937 — intervention group
Group type: EXPERIMENTAL
Intervention: PantoDict digital e‐learning program + conventional instruction (Group B)
Number of subjects: 36
Study 33153937 — intervention group
Group type: COMPARATOR
Intervention: Conventional instruction only (Group C)
Number of subjects: 36
Study 32053556 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraclonidine pre-SLT
Number of subjects: 35
Study 32053556 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac post-SLT
Number of subjects: 35
Study 32053556 — intervention group
Group type: COMPARATOR
Intervention: Placebo pre-SLT and post-SLT
Number of subjects: 35
Study 32053556 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 35
Study 35296912 — intervention group
Group type: EXPERIMENTAL
Intervention: TS-142 5 mg
Number of subjects: 24
Study 35296912 — intervention group
Group type: EXPERIMENTAL
Intervention: TS-142 10 mg
Number of subjects: 24
Study 35296912 — intervention group
Group type: EXPERIMENTAL
Intervention: TS-142 30 mg
Number of subjects: 24
Study 35296912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 33909409 — intervention group
Group type: EXPERIMENTAL
Intervention: SOLIS system (SOS-localization-based interaction screening)
Number of subjects: 0
Study 33909409 — intervention group
Group type: EXPERIMENTAL
Intervention: SOLIS system
Number of subjects: 0
Study 33909409 — intervention group
Group type: COMPARATOR
Intervention: Three other PPI detection methods (NanoBiT, SPR, pull-down assays)
Number of subjects: 0
Study 34706819 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT)
Number of subjects: 54
Study 34706819 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (OMT + respiratory training)
Number of subjects: 54
Study 34706819 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 54
Study 35737553 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS delivered over the DLPFC at Fp3 site for 10 mins at 1.5 mA intensity
Number of subjects: 112
Study 35737553 — intervention group
Group type: COMPARATOR
Intervention: Sham/control groups
Number of subjects: 112
Study 33384265 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive powered toothbrushes (PT group)
Number of subjects: 36
Study 33384265 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrushes (MT group)
Number of subjects: 36
Study 33384265 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MT and PT)
Number of subjects: 36
Study 616508090 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet condition (using a stylus and electronic tablet)
Number of subjects: 0
Study 616508090 — intervention group
Group type: COMPARATOR
Intervention: Model building condition (using materials to build enclosures and figurines)
Number of subjects: 0
Study 35985933 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 9167
Study 35985933 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (CT)
Number of subjects: 9167
Study 35985933 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin
Number of subjects: 9167
Study 34293959 — intervention group
Group type: EXPERIMENTAL
Intervention: Court-Type Traditional Thai Massage (CTTM)
Number of subjects: 46
Study 34293959 — intervention group
Group type: COMPARATOR
Intervention: Thai Hermit Exercise (THE)
Number of subjects: 46
Study 35260419 — intervention group
Group type: EXPERIMENTAL
Intervention: imlifidase (0.25 mg/kg single dose)
Number of subjects: 15
Study 35260419 — intervention group
Group type: COMPARATOR
Intervention: historical control cohort
Number of subjects: 15
Study 33623054 — intervention group
Group type: EXPERIMENTAL
Intervention: Barefoot running
Number of subjects: 41
Study 33623054 — intervention group
Group type: COMPARATOR
Intervention: Shod running
Number of subjects: 41
Study 33623054 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups during the 15-min run
Number of subjects: 41
Study 32797664 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster R‐CNN with ResNet‐50
Number of subjects: 1500
Study 32797664 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster R‐CNN with VGG‐16
Number of subjects: 1500
Study 32797664 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal group)
Number of subjects: 1500
Study 32797664 — intervention group
Group type: COMPARATOR
Intervention: Control group (disc group)
Number of subjects: 1500
Study 32797664 — intervention group
Group type: COMPARATOR
Intervention: Control group (injured group)
Number of subjects: 1500
Study 34496096 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide, bortezomib, and dexamethasone (PVd)
Number of subjects: 559
Study 34254934 — intervention group
Group type: EXPERIMENTAL
Intervention: Home environmental assessment and modifications delivered by occupational therapists
Number of subjects: 1331
Study 34254934 — intervention group
Group type: COMPARATOR
Intervention: Usual care (including falls prevention leaflet and routine care from general practitioner)
Number of subjects: 1331
Study 32574478 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Microphone
Number of subjects: 15
Study 32574478 — intervention group
Group type: EXPERIMENTAL
Intervention: CROS
Number of subjects: 15
Study 32574478 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Conduction Device on softband
Number of subjects: 15
Study 32574478 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral Routing of Signal (CROS)
Number of subjects: 15
Study 32574478 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 15
Study 32574478 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 15
Study 34775965 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium flow regulation
Number of subjects: 0
Study 34775965 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong flow regulation
Number of subjects: 0
Study 32688479 — intervention group
Group type: EXPERIMENTAL
Intervention: p[over ¯]_{c1}
Number of subjects: 0
Study 32688479 — intervention group
Group type: EXPERIMENTAL
Intervention: p[over ¯]_{c2}
Number of subjects: 0
Study 32688479 — intervention group
Group type: EXPERIMENTAL
Intervention: p[over ¯]_{c3}
Number of subjects: 0
Study 32688479 — intervention group
Group type: EXPERIMENTAL
Intervention: p[over ¯]_{c4}
Number of subjects: 0
Study 34252387 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐health‐based screening strategy consisting of repetitive one‐minute photoplethysmographic (PPG) pulse wave assessments using a certified smartphone app (Preventicus Heartbeats), followed by a confirmatory 14‐day ECG patch (CardioMem CM 100 XT) in case of abnormal findings.
Number of subjects: 4400
Study 34252387 — intervention group
Group type: COMPARATOR
Intervention: Routine symptom‐based screening.
Number of subjects: 4400
Study 33023495 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml 0.5% ropivacaine (Group A)
Number of subjects: 74
Study 33023495 — intervention group
Group type: COMPARATOR
Intervention: 10 ml normal saline (Group B)
Number of subjects: 74
Study 35430584 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) plus prednisone (P)
Number of subjects: 68
Study 35430584 — intervention group
Group type: COMPARATOR
Intervention: Continued ADT plus Abiraterone acetate (AA) plus prednisone (P)
Number of subjects: 68
Study 34663559 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 34663559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32842974 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated thoracic radiotherapy plus durvalumab
Number of subjects: 0
Study 32842974 — intervention group
Group type: COMPARATOR
Intervention: Conventionally fractionated thoracic radiotherapy plus durvalumab
Number of subjects: 0
Study 33217861 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based therapy (HBT)
Number of subjects: 42
Study 33217861 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (UP)
Number of subjects: 42
Study 35282662 — intervention group
Group type: EXPERIMENTAL
Intervention: ARNI (sacubitril/valsartan)
Number of subjects: 131
Study 35282662 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 131
Study 32833484 — intervention group
Group type: EXPERIMENTAL
Intervention: Active exercise training condition
Number of subjects: 90
Study 32833484 — intervention group
Group type: COMPARATOR
Intervention: Wait list symptom monitoring condition
Number of subjects: 90
Study 32220069 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous transplant
Number of subjects: 1909
Study 32220069 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic transplant
Number of subjects: 1909
Study 32220069 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival from relapse
Number of subjects: 1909
Study 32220069 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative risk of relapse
Number of subjects: 1909
Study 32220069 — intervention group
Group type: EXPERIMENTAL
Intervention: Late relapse incidence
Number of subjects: 1909
Study 32220069 — intervention group
Group type: EXPERIMENTAL
Intervention: Median time to late relapse
Number of subjects: 1909
Study 33034672 — intervention group
Group type: EXPERIMENTAL
Intervention: Videofluoroscopy-based predictive model incorporating DVH parameters of swallowing organs at risk (SWOARs)
Number of subjects: 38
Study 33034672 — intervention group
Group type: EXPERIMENTAL
Intervention: Videofluoroscopy-based predictive model incorporating DVH parameters of SWOARs
Number of subjects: 38
Study 32314891 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital guide plate (51 implants)
Number of subjects: 50
Study 32314891 — intervention group
Group type: COMPARATOR
Intervention: Routine implant restoration treatment (45 implants)
Number of subjects: 50
Study 35544369 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccine (50 μg each)
Number of subjects: 4016
Study 35544369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4016
Study 36201330 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-supported multicomponent exercise intervention (8 weeks)
Number of subjects: 229
Study 36201330 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 229
Study 34226462 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (20mg/kg/day for 14 days)
Number of subjects: 62
Study 34226462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (16mg/kg/day for 14 days)
Number of subjects: 62
Study 34226462 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (20mg/kg/day for 14 days)
Number of subjects: 62
Study 34226462 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 62
Study 34226462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 62
Study 34226462 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 62
Study 34267133 — intervention group
Group type: EXPERIMENTAL
Intervention: Information given 14 days before surgery (Group 1)
Number of subjects: 50
Study 34267133 — intervention group
Group type: EXPERIMENTAL
Intervention: Information given 3 days before surgery (Group 2)
Number of subjects: 50
Study 34267133 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 50
Study 34267133 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 50
Study 34653002 — intervention group
Group type: EXPERIMENTAL
Intervention: Vojta therapy (specific tactile input)
Number of subjects: 0
Study 34653002 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control)
Number of subjects: 0
Study 32020400 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation plus chemotherapy
Number of subjects: 293
Study 32020400 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 293
Study 34170716 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiography plus intravascular ultrasound (DSA + IVUS)
Number of subjects: 55
Study 34170716 — intervention group
Group type: COMPARATOR
Intervention: Angiography alone (DSA)
Number of subjects: 55
Study 33161773 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 1986
Study 33161773 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control
Number of subjects: 1986
Study 34602467 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality experience (30-min long, facilitated by research coordinator, for two weeks, 10 sessions)
Number of subjects: 24
Study 32252716 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Traffic Lights (MTL)
Number of subjects: 2194
Study 32252716 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Warning Labels (WL)
Number of subjects: 2194
Study 32252716 — intervention group
Group type: COMPARATOR
Intervention: Guideline Daily Amounts (GDA)
Number of subjects: 2194
Study 36991381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent esketamine infusion (6-hour intravenous infusion every 2 weeks for 3 months, starting at 0.05 mg/kg/h, max 0.2 mg/kg/h)
Number of subjects: 60
Study 36991381 — intervention group
Group type: COMPARATOR
Intervention: Continuous esketamine infusion (6 consecutive days of intravenous infusion)
Number of subjects: 60
Study 36991381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent esketamine infusion
Number of subjects: 60
Study 33586254 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 105
Study 33586254 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training with Blood Flow Restriction (RT+BFR)
Number of subjects: 105
Study 33586254 — intervention group
Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 105
Study 32583959 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided closed reduction
Number of subjects: 100
Study 32583959 — intervention group
Group type: COMPARATOR
Intervention: Standard landmark guided closed reduction
Number of subjects: 100
Study 34453669 — intervention group
Group type: EXPERIMENTAL
Intervention: Advocacy program
Number of subjects: 37
Study 34453669 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control
Number of subjects: 37
Study 33456366 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine maleate (CPM) 8 mg intravenous before induction of anesthesia
Number of subjects: 76
Study 33456366 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control Group)
Number of subjects: 76
Study 36102596 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibudilast
Number of subjects: 0
Study 36102596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32144735 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative endocrine therapy concurrent with chemotherapy for 24 weeks
Number of subjects: 70
Study 32144735 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 70
Study 33886921 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical restraint (bandage, tissues, sheets)
Number of subjects: 162
Study 33886921 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of aggressive behavior
Number of subjects: 162
Study 33886921 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention of falls
Number of subjects: 162
Study 33886921 — intervention group
Group type: EXPERIMENTAL
Intervention: Protection
Number of subjects: 162
Study 32560632 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver venous deprivation (LVD)
Number of subjects: 64
Study 32560632 — intervention group
Group type: COMPARATOR
Intervention: Portal vein embolization (PVE)
Number of subjects: 64
Study 32560632 — intervention group
Group type: EXPERIMENTAL
Intervention: LVD
Number of subjects: 64
Study 32560632 — intervention group
Group type: COMPARATOR
Intervention: PVE
Number of subjects: 64
Study 35651610 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (5 μg/kg every day for 6 days, then every other day until day 18)
Number of subjects: 111
Study 35651610 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard therapy)
Number of subjects: 111
Study 35651610 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 111
Study 34117198 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant administration of CYD‐TDV and Tdap vaccine
Number of subjects: 688
Study 34117198 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential administration of CYD‐TDV and Tdap vaccine
Number of subjects: 688
Study 34117198 — intervention group
Group type: COMPARATOR
Intervention: Both groups (concomitant and sequential)
Number of subjects: 688